Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026)

Atreya, Chintamani and Glynn, Simone and Busch, Michael and Kleinman, Steve and Snyder, Edward and Rutter, Sara and AuBuchon, James and Flegel, Willy and Reeve, David and Divine, Dana and Cohn, Claudia and Custer, Brian and Goodrich, Raymond and Benjamin, Richard J. and Razatos, Anna and Cancelas, Jose and Wagner, Stephen and MacLean, Michelle and Gelderman, Monique and Cap, Andrew and Ness, Paul (2019) Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026). Transfusion, 59 (9). pp. 3002-3025. ISSN 1537-2995

[img]
Preview
Text (Atreya-etal-Transfusion-2019-Proceedings-of-the-Food-and-Drug-Administration-public-workshop-on-pathogen-reduction)
Atreya_etal_Transfusion_2019_Proceedings_of_the_Food_and_Drug_Administration_public_workshop_on_pathogen_reduction.pdf
Final Published Version
License: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 logo

Download (427kB)| Preview

    Abstract

    On November 29, 2018, experts in the field of infectious diseases, pathogen reduction technologies (PRTs) and other participants from blood centers, academia, and industry gathered at the Food and Drug Administration (FDA) White Oak Campus in Silver Spring, Maryland, for a 2‐day public workshop entitled “Pathogen Reduction Technologies for Blood Safety.” The workshop opened with welcome remarks from Dr. Nicole Verdun, Director, Office of Blood Research and Review (OBRR), Center for Biologics Evaluation and Research (CBER), FDA, followed by introductory remarks from Dr. Peter Marks, Director, CBER, FDA. The first day of the workshop focused on blood‐borne infectious agents and their impact on blood safety, experiences of the American Red Cross, and other blood establishments in implementing FDA‐approved pathogen inactivation (PI) technology for plasma and platelets (PLTs) in the United States and novel PRTs under consideration for whole blood (WB) and red blood cells (RBCs). The second day opened with welcome remarks from Dr. Chintamani Atreya, Associate Director for Research, OBRR, CBER, FDA. The focus was on emerging innovations relevant to PRTs and potential alternatives to PRTs. The workshop concluded with remarks on insights for future research and development in this area for blood and blood product safety from infectious agents. A brief introduction of each session by the session moderator followed by a summary of the speaker presentation as submitted by the moderator and speaker are reported here.